(
151
Results
)
Filter
Only match titles
What are you looking for?
-
Category
-
Type
-
Year
-
Keywords
-
Author
Apply filters
Knowledge Hub
Collapse
-
A unified approach: Improving patient outcomes in severe asthma and comorbid eosinophilic diseases
-
CRSwNP, a Type 2 Inflammatory disease: Changing treatment paradigm
-
Exploring the Role of Type 2 Inflammation in Dermatologic Diseases
-
Navigating Type 2 Inflammation across the skin, airway, and esophagus
-
Progression of Type 2 Inflammatory Diseases in Different Organ Systems in Pediatric Patients
-
Targeted therapy for patients with severe eosinophilic asthma – an interactive conversation with experts
-
Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention?
-
Type 2 Inflammation: What every clinician should know
-
Yesterday’s vision is today’s opportunity to address Type 2 Inflammation in pediatric and adult atopic dermatitis patients
-
Breaking new ground: A closer look at Type 2 Inflammation in pediatric asthma
-
Can we break the cycle of lung function decline and asthma exacerbations driven by type 2 inflammation in asthma?
-
Childhood Asthma and the Impact of Type 2 Inflammation
-
Severe type 2 asthma: phenotypes and precision treatment for patients
-
Managing severe asthma and CRSwNP: Through the lens of Type 2 Inflammation
-
Targeting Type 2 mechanisms in patients with atopic dermatitis and comorbid Type 2 Inflammatory disease: A case-based reflection
Show more Sponsored Symposia (13)Show Less-
-
Allergic severe asthma and cat epithelia in COVID-19 pandemic: a case report
-
Asthma endotypes as risk factors for severe COVID-19 manifestations
-
Biological severe asthma treatment in Poland – pros and cons of drug programme
-
Bronchiectasis and severe asthma
-
Diagnosis and allocation to biologics in severe asthma – guidelines of the Polish Society of Allergology
-
Dupilumab and live-attenuated vaccines: experience with prior dupilumab use and yellow fever vaccine in patients with severe asthma from Brazil
-
EAACI Biologicals Guidelines – Recommendations for Severe Asthma
-
Efficacy of dupilumab in children with uncontrolled, moderate-to-severe type 2 asthma, with/without evidence of allergic asthma: the VOYAGE phase 3 study
-
Electronic Health in Severe Asthma
-
Focus on Patient. Personalised therapy for severe asthma
-
How does Type 2 mucosal inflammation influence susceptibility to SARS-CoV-2?
-
Immunotherapy in severe asthma (AIT)
-
Inhibiting Type 2 inflammation in atopic dermatitis with dupilumab modulates COVID-19 responses
-
Novel therapeutic approaches in severe asthma
-
Opportunities and Obstacles to treat severe asthma with new biologics based on experiences from real world practice
-
Severe Asthma and COVID-19
-
The basics of severe asthma – biomarkers
-
The clinical case of the great dupilumab efficacy in the treatment of the severe asthma comorbid with chronic rhinosinusitis with nasal polyps
Show more Event Resources (16)Show Less-
-
Association of endopeptidases, involved in SARS‐CoV‐2 infection, with microbial aggravation in sputum of severe asthma
-
COVID‐19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments
-
Enzymatic activity of ACE2 regulates type 2 airway inflammation in mice
-
Shielding against SARS-CoV-2 infections is not justified in children with severe asthma 
-
Severe asthma in adults does not significantly affect the outcome of COVID‐19 disease: results from the Italian Severe Asthma Registry
Show more Covid-19 (3)Show Less-
Website
Collapse
-
A 12 months real-life prospective study of lung function in patients with severe eosinophilic asthma undergoing therapy with ics/laba, lama, and anti IL5/5R monoclonal antibody
-
A novel approach of pooling donors for basophil testing to diagnose type 2 autoimmune chronic spontaneous urticaria
-
A proof-of-concept study on an artificial intelligence model for biological therapy decision-making in severe asthma
-
A proof-of-concept study on an artificial intelligence model for biological therapy decision-making in severe asthma
-
Adverse reactions to biologicals in severe asthma
-
Allergen immunotherapy in patients with allergic rhinitis and asthma associated with reduced risk of severe COVID-19
-
Allergy and Asthma – Session 1: Diagnosing Asthma
-
Allergy and Asthma – Session 2: Precision medicine in pediatric asthma
-
An interim analysis of a multi-center, oPEn label, Randomized study to investigate the saFEty of an optimal acCelerated scheme for immunoTherapy in adolescent and adult patients with moderate to severe AR with or without asthma in China. (PERFECT)
-
Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma
-
Association of asthma severity with high sensitivity C-reactive protein (hsCRP) in the all-age asthma cohort ALLIANCE
-
Asthma 2
-
AstraZeneca – Transforming severe asthma respiratory care: the clinical experience
-
Baseline Characteristics of Patients with Severe Asthma in Spain according to biological treatment use: BREATHE study
-
Baseline disease burden in severe asthma patients treated with biologics, and eligible but not treated: Spanish patients in the ISAR Registry
-
Benefits of the combination of biologics in the control of a patient with high type 2 profile: a case report
-
Benralizumab effectiveness in severe eosinophilic asthma patients from Central Eastern Europe and Baltics: BREEZE study
-
Cannabinoid agonist WIN55,212-2 improves bronchial epithelial barrier alterations in the context of viral infection and type 2 inflammation
-
Causes of death in patients diagnosed with severe asthma in our area- 10 years observational study
-
Clinical Characteristics of Patients with Severe Asthma by Different Elevated Biomarkers Classifications: Patients from Spain in the ISAR Registry
-
Clinical effects of dupilumab in patients with rhinosinusitis, nasal polyposis, and severe uncontrolled asthma with t2 phenotype, after 12 months of treatment
-
Clinical implications of biologic therapies in comorbid severe asthma and CRSwNP
-
Clinical profile of 457 Latin-American severe asthma patients in Mexico: differences between those who are and those who are not on biologics (OMA, DUPI, anti-IL5)
-
Comprehensive Analysis Of Pediatric ICU Admissions For Severe Acute Asthma Over A Decade
-
Cytometric detection of Der p 1 and Der p 2 binding to Basophils (CytoBas) enables precise determination of house dust mite sensitization in patients with asthma and allergic rhinitis
-
Cytometric detection of Der p 1 and Der p 2 binding to Basophils (CytoBas) enables precise determination of house dust mite sensitization in patients with asthma and allergic rhinitis
-
Dupilumab Reduces FeNO levels and Exacerbations and Improves Asthma Control with Inhaled Corticosteroid Withdrawal: a Phase 2 Study
-
Dupilumab treatment effectively reduces nasal type 2 cytokine production following acetylsalicylic acid provocation in N-ERD patients
-
Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis
-
Dupilumab-induced skin reaction in a patient with severe asthma and chronic rhinosinusitis with nasal polyposis and without prior skin conditions
-
Effect of baseline long-acting muscarinic antagonist (LAMA) use on inhaled corticosteroid dose reduction in patients with severe eosinophilic asthma treated with benralizumab: SHAMAL post-hoc analysis
-
Efficacy and Safety of Dupilumab in Children Aged 6 Months to 5 Years With Atopic Dermatitis With and Without Type 2 Comorbidities
-
Efficacy of Dupilumab in patients over 50 years of age with severe asthma
-
Efficacy of Rilzabrutinib on Asthma Control: Results From a Double-Blind Placebo-Controlled Phase 2 Study
-
Efficacy of Rilzabrutinib on Asthma Quality of Life: Results From a Double-Blind Placebo-Controlled Phase 2 Study
-
Elevating patient treatment outcomes in Severe Asthma
-
Elevating patient treatment outcomes in Severe Asthma & comorbid CRSwNP
-
Emerging therapies and approaches for achieving remission in severe asthma
-
Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients With Uncontrolled Moderate-to-Severe Asthma: The VESTIGE Trial
-
Evaluation of remission of Severe Asthma treated with monoclonal antibodies according to different definitions: a single center cohort
-
Evaluation of the Pediatric Patients with Severe Eosinophilic Asthma Treated with Mepolizumab
-
Expansion of allergen-specific type 2 memory B cells with an altered phenotype after immunotherapy for bee venom or ryegrass pollen allergy
-
First clinical practice of using biologic therapy with dupilumab in combination with allergen-specific immunotherapy in a patient with severe atopic dermatitis and bronchial asthma
-
GSK – Elevating patient treatment outcomes in severe asthma and CRSwNP
-
Immunodeficiency spectrum in patients with severe asthma receiving biologicals
-
Immunodeficiency spectrum in patients with severe asthma receiving biologicals
-
Immunostimulatory or immunosuppressive role of type 2 innate lymphoid cells
-
Impact of asthma on severe food-induced allergic reactions: a systematic review and meta-analysis
-
Infective asthma exacerbations in severe asthmatic patients receiving biological drugs
-
Involvement of Janus kinase (JAK)-dependent Bcl-xL overexpression in steroid resistance of group 2 innate lymphoid cells (ILC2s) in asthma
-
Long-Term Efficacy of Mepolizumab at 5 Years in Patients with Severe Asthma
-
Mepolizumab simultaneously improves clinical outcomes in severe CRSwNP and asthma in the SYNAPSE study: Focus on global airway disease
-
Mid-Term Impact of Non-Pharmaceutical Interventions on the Epidemiology of Hospitalizations for Severe Asthma Exacerbation in Children : A Time-Series Analysis
-
Molecular allergen sensitizations drive phenotypes of severe asthma in children: evidence from a megacity cohort (SAMP)
-
Monitoring Patients with Severe Eosinophilic Asthma Receiving Benralizumab in Allergy Centers in Greece for 8-12 months – REALISM-A Study (gReek rEAl Life regIStry of benralizuMab among Allergists)
-
Novel roles of type 2 innate lymphoid cells in allergic diseases
-
Omalizumab Combined Chinese Traditional Medicine in a Complicated Severe Asthma after Bronchial Thermoplasty
-
OverSEA: European Delphi Consensus Study on Best Practices for patients with Severe Eosinophilic Asthma and comorbid CRSwNP
-
Patients with severe eosinophilic asthma starting anti-IL5 treatment after 2018 have better preserved lung function compared to the patients who started treatment earlier
-
Predictors of biological therapy in severe asthma patients. An ambispective study from the BIOBADALER consortium
-
Predictors of biological therapy in severe asthma patients. An ambispective study from the BIOBADALER consortium
-
Pro-inflammatory cytokines (IL-6 and TNF), influence of the JAK-STAT cascade and negative regulation of the Hyppo pathway in the severe asthma phenotype
-
Progression of Underlying Disease in Pediatric Severe Asthma
-
Progressive increase of the intervals between omalizumab administration in severe asthma
-
Real-life data analysis of severe asthma patients undergoing biologic therapy: OCS consumption and respiratory function evaluation
-
Real-world effectiveness of dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) is independent of comorbidities, sinus surgery history and level of type 2 inflammation: Findings from CHRINOSOR
-
Regulation of the type 2 imprint by microbes and environmental factors
-
Relevance of IL-17-associated immune pathways and CXCL10 expression in severe childhood asthma
-
Relevance of IL-17-associated immune pathways and CXCL10 expression in severe childhood asthma
-
Retrospective analysis of quantitative CT characteristics of patients with severe asthma treated with biological agents: KoSAR registry
-
Serum Levels of Cytokine in Individuals with Severe Asthma with Obesity
-
Serum cytokine profiles of pediatric normal weight asthma and overweight/obese asthma and their correlation with pulmonary function indices
-
Severe Asthma and Obesity: A retrospective study
-
Severe Eosinophilic Asthma later recognized as EGPA treated with Benralizumab
-
Severe asthma in pediatrics and Dupilumab after failure with Omalizumab
-
Severe asthma or COPD with eosinophilic inflammation? – from uncertainty to remission under anti-IL-5R therapy
-
Stability of steroid-dependent severe asthma during 5-year follow-up
-
Successful treatment of severe asthma after switch of biologics. A case report
-
Successfully managing severe asthma
-
T2 inflammatory profile of 457 Latin-American severe asthma patients in Mexico: differences between those who are and those who are not on biologics (OMA, DUPI, anti-IL5)
-
Targeting TSLP in severe asthma
-
The Influence of Dupilumab on the Nasal and Gastrointestinal Microbiome in Diffuse Type 2 Chronic Rhinosinusitis
-
The impact of Type 2- targeted biological therapies on persistent cough in adults with cough variant- or cough predominant asthma
-
The relevance of IL-5 biology in severe asthma
-
Toward Optimal disease control: impact of maintenance inhaler therapy and device transition in severe asthma patients undergoing monoclonal antibody treatment
-
Transforming severe asthma respiratory care: the clinical experience
-
Treatment of severe asthma (update)
-
Type 2 immunity at the mucosal barriers
-
Use of biologics in severe uncontrolled asthma at National Institute of Pediatrics 2020-2023
-
Use of biologics in severe uncontrolled asthma at National Institute of Pediatrics 2020-2023
-
Variables predicting clinical remission among adults with severe asthma treated with biologic agents
-
Asthma control, lung function, and quality of life in pediatric patients with severe asthma undergoing biological treatment
-
Biologics have Solved the Problem of Type 2 Asthma
-
Characteristics of asthma phenotypes: Does coexistence of allergic and eosinophilic asthma increase asthma severity?
-
Decoding Asthma Therapies: Transcriptomic differences between benralizumab and mepolizumab treatment in patients with severe eosinophilic asthma
-
Dietary intervention with fructo-oligosaccharides in a mouse-model for house dust mite allergy enhances type 1, while lowering HDM specific type 2 responses in the lungs
-
Effects of dupilumab on quality of life and airflow obstruction in refractory type 2 high severe unified airways disease
-
Lung Function Improvement is Associated With Better Asthma Control in Adolescents and Adults Aged 12 Years and Older With Moderate-to-Severe Type 2 Asthma: A Post Hoc Analysis of QUEST
-
Lung Function Responder Rates in the VOYAGE study in Children with Moderate-to-Severe Type 2 Asthma Receiving Dupilumab at Week 52
-
Prevalence of severe fatigue and its contributing factors in patients with severe asthma
-
Real-world effectiveness of biologics in patients with severe asthma: analysis of the Korean Severe Asthma Registry (KoSAR)
-
The effect of therapies targeting Type 2 inflammation on Neutrophil Extracellular Traps (NETs) and Extracellular Eosinophilic Traps (EETs) in severe CRSwNP
-
The effect of therapies targeting Type 2 inflammation on Neutrophil Extracellular Traps (NETs) and Extracellular Eosinophilic Traps (EETs) in severe CRSwNP
-
The m6A demethylase FTO mediates type 2 inflammation in asthma by regulating STAT6 mRNA stability
-
The triple type 2 signature is associated to asthma severity and comorbidity with CRS
-
Type 2-high airway inflammation in childhood asthma distinguishes a more severe phenotype
-
Indirect case matched comparison of dupilumab versus benralizumab on mannitol airway hyperresponsiveness in type 2 high severe asthma
-
Real-world change in asthma symptom control and oral corticosteroid use in patients with severe asthma treated with mepolizumab stratified by atopic status: Post hoc analysis of REALITI-A at 2 years
-
Severe asthma and sleep disorders: a Severe Asthma Network Italy (SANI) analysis
-
Characteristics and Asthma Control Status of Severe Asthma Patients in the Korean Severe Asthma Registry-2 (KoSAR-2)
Show more Sessions (108)Show Less-